InVitro International

As of June 30, 2026, InVitro International carries a market capitalization of 1.90M, placing it among publicly traded companies globally. Its enterprise value stands at 913,495.71, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, InVitro International has 22.26M shares outstanding.

As of June 30, 2026, InVitro International trades at a trailing price-to-earnings ratio of 30.06. The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 1.12.

As of June 30, 2026, InVitro International trades at an EV/EBITDA multiple of 19.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. InVitro International trades at an EV/FCF ratio of 307.47, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 913,495.71 versus a market cap of 1.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, InVitro International maintains a current ratio of 11.56, meaning it holds 11.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, InVitro International posted a return on equity (ROE) of 3.75, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.69 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.14, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.23, useful for judging operating efficiency across full business cycles. The company generates approximately 154,211.40 in revenue per employee across its workforce of 5.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.75 indicates how many times InVitro International sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, InVitro International recorded 2,589.00 in income tax expense. That works out to an effective tax rate of 3.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 65,646.00, leaving 63,057.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 16, 2026, InVitro International's stock has declined approximately 22.08% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.

Over the twelve months ended June 30, 2026, InVitro International generated 771,057.00 in revenue and converted that into 63,057.00 in net income, yielding earnings per share of 0.00. EBITDA reached 46,141.00, while operating income came in at 34,337.00.

As of June 30, 2026, InVitro International holds 1.23M in cash and equivalents against 240,298.00 in total debt, resulting in a net debt position of -1.23M. Total book value stands at 1.70M, with working capital of 1.38M providing operational flexibility.

InVitro International produced 4,068.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1,097.00 in capital expenditures, free cash flow totaled 2,971.00 - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, InVitro International posted a gross margin of 81.88, reflecting its pricing power and cost economics. The operating margin of 4.45 and net profit margin of 8.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.15, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

As of June 30, 2026, InVitro International has an Altman Z-Score of 5.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.